Overview of FK506 in Transplantation

Overview

Journal Clin Transpl

Specialty General Surgery

Date 1990 Jan 1

PMID 1715740

Citations 6

Authors

J J Fung

K Abu-Elmagd

S Todo

R Shapiro

A Tzakis

M Jordan

J Armitage

A Jain

M Alessiani

M Martin

Affiliations

Soon will be listed here.

Abstract

FK506 is a potent immunosuppressive agent which is undergoing clinical testing in liver, kidney, heart, and bone marrow transplantation. It has been shown to effectively prevent and reverse ongoing rejection in these models. From the outset, FK506 was used with low-dose steroids to treat 110 primary liver, 30 heart, and 66 kidney graft recipients. FK506 was also used in the setting of complications related to CsA or to ongoing chronic or acute rejection. One hundred seventy-three liver, 21 kidney, 10 heart, and 11 bone marrow recipients were converted to FK506 and low-dose steroids, from a combination of CsA, steroids, and/or Aza. A randomized, prospective trial comparing FK506 with CsA in primary liver transplantation has verified the lower incidence of rejection and greater ease in treating rejection episodes, with fewer adverse effects. In summary, FK506 has proven to be an effective baseline immunosuppressive agent, as well as a dose-adjustable agent for the treatment of rejection.

Citing Articles

New Developments and Challenges in Liver Transplantation.

Khalil A, Quaglia A, Gelat P, Saffari N, Rashidi H, Davidson B J Clin Med. 2023; 12(17).

PMID: 37685652 PMC: 10488676. DOI: 10.3390/jcm12175586.

Case Report: Let Us Not Forget the Treatment That Some Patients Have Received-The Brief 50-Year History of a Kidney Transplant Survivor.

Nordheim E, Raki M, Midtvedt K Front Med (Lausanne). 2022; 9:906925.

PMID: 35685423 PMC: 9170981. DOI: 10.3389/fmed.2022.906925.

Targeting Metabolism as a Platform for Inducing Allograft Tolerance in the Absence of Long-Term Immunosuppression.

Cheng C, Lee C, Oh B, Furtmuller G, Patel C, Brandacher G Front Immunol. 2020; 11:572.

PMID: 32328063 PMC: 7161684. DOI: 10.3389/fimmu.2020.00572.

High Dimensional Renal Profiling: Towards a Better Understanding or Renal Transplant Immune Suppression.

Castro-Rojas C, Alloway R, Woodle E, Hildeman D Curr Transplant Rep. 2019; 6(1):60-68.

PMID: 31595214 PMC: 6781878. DOI: 10.1007/s40472-019-0225-1.

Mycophenolate mofetil enhances the negative effects of sirolimus and tacrolimus on rat kidney cell metabolism.

Klawitter J, Klawitter J, Schmitz V, Shokati T, Epshtein E, Thurman J PLoS One. 2014; 9(1):e86202.

PMID: 24497939 PMC: 3907404. DOI: 10.1371/journal.pone.0086202.

References

Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T . FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987; 40(9):1256-65. DOI: 10.7164/antibiotics.40.1256. View

Demetris A, Fung J, Todo S, McCauley J, Jain A, Takaya S . Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation. 1992; 53(5):1056-62. PMC: 2962565. DOI: 10.1097/00007890-199205000-00017. View

Starzl T, Demetris A . Liver transplantation: a 31-year perspective. Part II. Curr Probl Surg. 1990; 27(3):117-78. DOI: 10.1016/0011-3840(90)90030-9. View

Ochiai T, Nakajima K, Nagata M, Suzuki T, Asano T, Uematsu T . Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc. 1987; 19(1 Pt 2):1284-6. View

Todo S, Fung J, Starzl T, Tzakis A, Demetris A, Kormos R . Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg. 1990; 212(3):295-305; discussion 306-7. PMC: 1358160. DOI: 10.1097/00000658-199009000-00008. View

Sullivan K, Witherspoon R, Storb R, Deeg H, Dahlberg S, Sanders J . Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood. 1988; 72(2):555-61. View

Todo S, Ueda Y, Demetris J, Imventarza O, Nalesnik M, Venkataramanan R . Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery. 1988; 104(2):239-49. PMC: 2972580. View

Tamura K, Kobayashi M, Hashimoto K, Kojima K, Nagase K, Iwasaki K . A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc. 1987; 19(5 Suppl 6):23-9. View

Shapiro R, Jordan M, Fung J, McCauley J, Johnston J, Iwaki Y . Kidney transplantation under FK 506 immunosuppression. Transplant Proc. 1991; 23(1 Pt 2):920-3. PMC: 2979325. View

10.

Fung J, Todo S, Jain A, McCauley J, Alessiani M, Scotti C . Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc. 1990; 22(1):6-12. PMC: 2903869. View

11.

Murase N, Kim D, Todo S, Cramer D, Fung J, Starzl T . Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation. 1990; 50(2):186-9. PMC: 2978534. DOI: 10.1097/00007890-199008000-00002. View

12.

. Second International Workshop on FK 506. A potential breakthrough in immunosuppression: clinical implications. October 31, 1989, Barcelona, Spain. Proceedings. Transplant Proc. 1990; 22(1):5-113. View

13.

Thomson A . Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. Transplant Proc. 1990; 22(1):100-5. View

14.

Armitage J, Kormos R, Griffith B, Hardesty R, Fricker F, Stuart R . A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc. 1991; 23(1 Pt 2):1149-52. PMC: 2978527. View

15.

Murase N, Kim D, Todo S, Cramer D, Fung J, Starzl T . Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. Transplant Proc. 1990; 22(1):74-5. PMC: 2903852. View

16.

Demetris A, Fung J, Todo S, Banner B, Zerbe T, Sysyn G . Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc. 1990; 22(1):25-34. PMC: 2903856. View

17.

Markus P, Cai X, Ming W, Demetris A, Fung J, Starzl T . Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation. 1991; 52(4):590-4. PMC: 2975544. DOI: 10.1097/00007890-199110000-00002. View

18.

Billingham M . Some recent advances in cardiac pathology. Hum Pathol. 1979; 10(4):367-86. DOI: 10.1016/s0046-8177(79)80043-x. View

19.

Harding M, Galat A, Uehling D, Schreiber S . A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature. 1989; 341(6244):758-60. DOI: 10.1038/341758a0. View